James Lah, MD
Enriched profileProfessor of Neurology; Alice and Roy Richards Chair for Alzheimer's Research, Department of Neurology · Emory University
James Lah is Professor of Neurology; Alice and Roy Richards Chair for Alzheimer's Research, Department of Neurology at Emory University. OpenAlex indexes 550 publications with 42,363 citations (h-index 103); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the findmyKOL directory.
Data verified 9 Oct 2026
Overview
Updated 14 Oct 2026
James Lah, MD PHD, is Professor of Neurology at Emory University. The public record shows 550 publications with 42,363 citations (h-index 103), centered on Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Neuroinflammation and Neurodegeneration Mechanisms. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 3 companies, 7 NIH-funded awards (1996–2026).
- Most recent indexed publication: 2026 · Molecular psychiatry
- Top research focus: Dementia and Cognitive Impairment Research
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 26 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 294.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Sponsor: Washington University School of Medicine
- Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Sponsor: Emory University
- A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Sponsor: Washington University School of Medicine
Industry payments
Updated 14 Oct 2026
3 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year20252 payments
- Roche Diagnostics CorporationProgram year20221 payment
- Eisai Inc.Program year20221 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Cholinesterase Inhibitor42.5%Donepezil Hcl76%Galantamine Er13%Rivastigmine12%Part D<11 patientsSSRI26.4%Sertraline Hcl51%Escitalopram Oxalate37%Trazodone Hcl12%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
7 NIH research awards on record, funded 1996–2026 per NIH RePORTER. The latest:
- Explainable and Ethical AI for Studying Alzheimer's Disease
Emory University
FY2026$679,906R01AG089806 - The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's Disease
Emory University
FY2025$6,871,445R01AG070937
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Life's Essential 8: Essential for Brain and Cognitive Health.
Journal of the American Heart Association
Review2026 - Circulating Progenitor Cells, Regenerative Capacity and Cognition: Evidence From 2 Community-Based Cohorts.
Arteriosclerosis, thrombosis, and vascular biology
Article2026 - Education, Sex, and Age Shape Rey Complex Figure Performance in Cognitively Normal Adults: An Interpretable Machine Learning Study.
Journal of clinical medicine
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Variant of TREM2 Associated with the Risk of Alzheimer's DiseaseArticle2,561 citations2012
- 03
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
PhD (combined MD/PhD, Medical Scientist Program, Ohio State University School of Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cnd.emory.edu ↗ - BS with honors
Duke University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curealz.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curealz.org ↗
Secondary affiliations
appointments beyond the home institution- Director
Cognitive Neurology Program, Emory University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curealz.org ↗ - Associate Director and Clinical Core Leader
Emory Goizueta Alzheimer's Disease Research Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curealz.org ↗ - Associate Director
Goizueta Brain Health Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curealz.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →yahoo.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Keith Delman, MD
Emory University
John Puskas, MD
Emory University
Craig Hofmeister, MD
Emory University
Martha Arellano, MD
Emory University
Paul Ridker, MD
Brigham and Women's Hospital
Edward Giovannucci, MD, ScD, MPH
Harvard T.H. Chan School of Public Health
Stephen Chanock, MD
National Cancer Institute (NCI)
Wei Zheng, MD, PhD, MPH
Vanderbilt University Medical Center